{
  "extraction_metadata": {
    "extraction_date": "2025-08-16 00:59:25",
    "total_papers_processed": 3,
    "note": "All data includes direct quotes and source locations for verification"
  },
  "azacitidine": [
    {
      "complete_response": 66.0,
      "partial_response": null,
      "marrow_complete_response": 50.0,
      "marrow_optimal_response": null,
      "pfs_median": null,
      "os_median": 8.1,
      "efs_median": null,
      "sae_frequency": null,
      "ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "non_ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "citation": "Short Nicholas J, Muftuoglu Muharrem, Ong Faustine et al. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. Journal of hematology & oncology (2023)",
      "pmid": "37422688",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37422688/",
      "cmml_sample_size": null,
      "ras_mutant_sample_size": null,
      "non_ras_mutant_sample_size": null,
      "key_findings": "",
      "study_design": "",
      "patient_population": "",
      "treatment_details": "",
      "supporting_quotes": [],
      "data_source_location": "Abstract",
      "reference_note": "See PMID 37422688 - Abstract",
      "verification_url": "https://pubmed.ncbi.nlm.nih.gov/37422688/"
    },
    {
      "complete_response": null,
      "partial_response": null,
      "marrow_complete_response": null,
      "marrow_optimal_response": null,
      "pfs_median": null,
      "os_median": null,
      "efs_median": null,
      "sae_frequency": null,
      "ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "non_ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "citation": "Patnaik Mrinal M, Tefferi Ayalew Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management. American journal of hematology (2022)",
      "pmid": "34985762",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34985762/",
      "cmml_sample_size": null,
      "ras_mutant_sample_size": null,
      "non_ras_mutant_sample_size": null,
      "key_findings": "",
      "study_design": "",
      "patient_population": "",
      "treatment_details": "",
      "supporting_quotes": [],
      "data_source_location": "Abstract",
      "reference_note": "See PMID 34985762 - Abstract",
      "verification_url": "https://pubmed.ncbi.nlm.nih.gov/34985762/"
    },
    {
      "complete_response": null,
      "partial_response": null,
      "marrow_complete_response": null,
      "marrow_optimal_response": null,
      "pfs_median": null,
      "os_median": 36.0,
      "efs_median": null,
      "sae_frequency": null,
      "ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "non_ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "citation": "Patnaik Mrinal M, Lasho Terra Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review. Hematology. American Society of Hematology. Education Program (2020)",
      "pmid": "33275673",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33275673/",
      "cmml_sample_size": null,
      "ras_mutant_sample_size": null,
      "non_ras_mutant_sample_size": null,
      "key_findings": "",
      "study_design": "",
      "patient_population": "",
      "treatment_details": "",
      "supporting_quotes": [],
      "data_source_location": "Abstract",
      "reference_note": "See PMID 33275673 - Abstract",
      "verification_url": "https://pubmed.ncbi.nlm.nih.gov/33275673/"
    }
  ],
  "decitabine": [],
  "hydroxyurea": []
}